Loading...
Market
What will be the market share of Pfizer and Sangamo's Hemophilia A gene therapy by December 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Industry reports and market analysis
Story
Pfizer and Sangamo's AFFINE Study Shows Positive Phase 3 Results for Hemophilia A Gene Therapy
Jul 24, 2024, 11:02 AM
Pfizer has announced positive topline results from its Phase 3 study of a gene therapy candidate for Hemophilia A. The gene therapy, developed in collaboration with Sangamo Therapeutics, met its primary and key secondary objectives in the pivotal AFFINE study. This included a statistically significant reduction in annualized bleeding rates (ABR) from week 12 to month 15 post-infusion compared to routine factor VIII prophylaxis, with a reduction from 4.73 to 1.24 (p=0.0040). Despite these promising results, questions remain about the long-term durability and commercial viability of the therapy. Additionally, 84% of patients achieved more than 5% of normal factor VIII levels, although critical details about the use of immunosuppressants were not provided. Pfizer's gene therapy aims to offer a new treatment option for adults with moderately severe to severe Hemophilia A. Cash from Pfizer, however, is unlikely for another few months.
View original story
Similar markets
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Reduction by <25% • 25%
Reduction by 25-50% • 25%
Reduction by 50-75% • 25%
Reduction by >75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%